TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation of a Phase 1/2 clinical trial in combination with tislelizumab and...
Hence then, the article about anbogen receives fda clearance to initiate phase 1 2 trial of abt 301 triplet therapy for advanced colorectal cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer )
Also on site :
- Natural gas line rupture stops traffic on 5 Freeway in Castaic
- 30–35 terrorists on radar: Army steps up counterterror ops in J&K; intense vigil amid 'Chillai Kalan'
- Nine Years After Carrie Fisher Died, Billie Lourd Says Mom “Lives on Through Joy” With Kids, Dad Bryan Lourd